Equities

Lincoln Pharmaceuticals Ltd

LINCOLN:NSI

Lincoln Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)728.90
  • Today's Change2.85 / 0.39%
  • Shares traded37.02k
  • 1 Year change+45.05%
  • Beta0.8460
Data delayed at least 15 minutes, as of Sep 20 2024 11:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,5241,1381,153
Total Receivables, Net2,1601,7081,634
Total Inventory772700727
Prepaid expenses3.991.769.28
Other current assets, total7.501234.91
Total current assets4,4673,6723,528
Property, plant & equipment, net1,8251,5691,476
Goodwill, net------
Intangibles, net3.262.953.83
Long term investments1.224.7617
Note receivable - long term661601277
Other long term assets2.722.871.92
Total assets7,0035,8745,344
LIABILITIES
Accounts payable724512717
Accrued expenses696159
Notes payable/short-term debt112020
Current portion long-term debt/capital leases------
Other current liabilities, total118130109
Total current liabilities923723905
Total long term debt000
Total debt112020
Deferred income tax1157965
Minority interest------
Other liabilities, total374745
Total liabilities1,0758491,015
SHAREHOLDERS EQUITY
Common stock200200200
Additional paid-in capital646646646
Retained earnings (accumulated deficit)5,0864,1833,484
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(4.17)(4.78)(1.8)
Total equity5,9285,0254,329
Total liabilities & shareholders' equity7,0035,8745,344
Total common shares outstanding202020
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.